AI-Assisted Characterization of Psychedelic Clinical Trials from ClinicalTrials.gov
Bottom line: AI analysis of ClinicalTrials.gov suggests psychedelic research is expanding, with psilocybin leading in trials, but gaps remain in coverage and diversity of studies.
ClinicalTrials.gov holds over 350,000 records. An AI recently combed through them, identifying 700 trials involving psychedelics. That’s more than 2,000 participants. The data shows a field in motion. It also shows gaps, limitations, and a need for more research—especially in places where mental health care is scarce.
The AI That Sifts Through the Psychedelic Sea
A paper published in Trials in October 2026 describes the first large-scale use of AI to analyze psychedelic clinical trials. Researchers used a large language model (LLM) called Claude (Anthropic) to parse data from ClinicalTrials.gov. The goal was to understand the scale of psychedelic research and track how it has evolved over time.
The AI was given access to the registry’s API and asked to pull data on trials involving classic psychedelics and their derivatives. The core set of compounds included psilocybin, MDMA, LSD, DMT/5-MeO-DMT, ayahuasca, and ibogaine. Ketamine and esketamine were treated as a comparator class because they are already used in mental health treatment.
By January 2026, the AI had identified 412 trials, 256 of which involved patients. Psilocybin was the most common compound, with 244 trials. MDMA and LSD followed, with 99 and 13 trials, respectively. The data shows a field moving forward, but not yet fully realized.
The Numbers Behind the Mind
Psilocybin had 244 trials, 181 of which involved patients. Of these, 74 focused on depression, the leading indication. Ketamine and esketamine had 300 trials, with 237 of them also focused on depression. This suggests that the medical community is increasingly interested in using psychedelics for mood disorders.
MDMA, with 99 trials, is making a significant impact. Of those, 35 focused on PTSD, with a clear trend toward phase 3 trials. LSD had only 13 trials, all on anxiety. This shows the field is broad, but still uneven in its focus.
Only 24 core-set trials were registered as phase 3, with 13 of them involving psilocybin. These phase 3 trials plan to enroll over 1,900 participants. That’s a large commitment, but also a reminder that most trials are still in earlier stages.
The Hidden Landscape of Psychedelic Research
The study also highlights where the research is being done. Only 5 patient trials (2%) had a site in a low- or middle-income country. That’s a gap. Psychedelics could help people in regions where mental health care is limited, but the research isn’t reaching there yet.
The AI’s approach had limitations. It underestimated the number of records for some compounds. The researchers say the AI complements, but doesn’t replace, manual review. The accuracy of its findings hasn’t been fully tested.
The study also looked at the endpoints used in trials. For psilocybin trials in depression, 56% used a depression rating scale, with the MADRS being the most common. Only 41% excluded adults over 65, and none enrolled adolescents. This shows the field is focusing on adults, but is still learning about how psychedelics affect different age groups.
Frequently Asked Questions
What is the significance of the AI-assisted analysis?
The AI-assisted analysis provides a structured, reproducible overview of the psychedelic clinical landscape. It helps identify trends, gaps, and opportunities for further study.
How accurate is the AI’s data?
The AI’s approach is innovative, but it complements rather than replaces systematic review. The accuracy of its findings against manual extraction remains to be quantified. The data might not be entirely accurate for all compounds.
What are the key findings of the study?
The study found that psilocybin is the most studied compound, with a significant number of trials focused on depression. MDMA is leading in the treatment of PTSD, while LSD is being explored for anxiety. The research also highlights the geographical distribution of trials and the diversity of endpoints used.
Why is the geographical distribution of trials important?
The geographical distribution of trials is important because it reflects the accessibility and availability of resources for psychedelic research. The study found that only a small number of trials are conducted in low- or middle-income countries, which could limit the potential impact of these compounds in regions where they are needed most.
What are the limitations of the study?
The study acknowledges that the AI’s approach has limitations, particularly in underestimating the number of records for some compounds. It also notes that the data is still evolving, and more research is needed to fully understand the potential and risks of psychedelics in mental health treatment.
Sources
- ¶AI-assisted characterization of psychedelic clinical trials from ClinicalTrials.gov – Trials, 2026
- ¶Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians – Drugs, 2026
- ¶Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review – Europe PMC, 2026
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
